Voglibose

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

伏格列波糖是缬醇胺的 N-取代衍生物，对 α-葡萄糖苷酶具有优异的抑制活性，并且对高血糖和高血糖引起的各种疾病具有作用。

Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus. Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest. Voglibose has fewer side effects than both acarbose and miglitol. But acarbose has an edge over voglibose in terms of efficacy (FPG, PPHG, HBA1c).

——

——

AO-128, AO 128, Glustat, Voglibose, Voglib

Endocrinology/Hormones

RAAS

α-glucosidase

Metabolic Disease

——

83480-29-9

267.28

C10H21NO7

>98% (HPLC)

H2O : ≥ 200 mg/mL; 748.28 mM

[C@]1([C@H]([C@@H]([C@H]([C@H](C1)NC(CO)CO)O)O)O)(O)CO

(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol

(-20℃)

With Ice Pack

≥ 2 years